Latest Breaking News On - International conference on molecular - Page 8 : comparemela.com

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Plan to Submit Application for Accelerated Approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in H1 2024 Expects to Begin Enrollment in Phase 3 Confirmatory.

United statesDan patersonInternational conference on molecularPancreatic cancer action network panPatient impactOvarian cancer foundationEuropean network of gynaecological oncological trialHead of regulatory affairsWorld ovarian cancer coalitionChugai pharmaceutical co ltdExchange commissionRaf and mek programFoundation incPatient impact advisory committeeDrug administrationVerastem oncology

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Adicet bioChen schorAdicet bio incDrug administrationDevelopment rd expensesSociety for immunotherapy of cancerInternational conference on molecularDevelopment for solid tumorsReports third quarterProvides businessChief executive officerOperational highlightsInternational conferenceMolecular targetsThird quarterPrivate securities litigation reform act

Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates

Preliminary data for FPI-2265 (225Ac-PSMA I&T) in approximately 20 to 30 patients on track for Q1 2024 Data from Cohort 2 of the FPI-1434 Phase 1 study.

United statesJeremy benderAmanda crayTeresa bitettiJohn valliantFusion pharmaceuticals incInternational conference on molecularNiowave incFusion pharmaceuticalsInvestor relations corporate communicationsPrnewswire fusion pharmaceuticals incExecutive officer john valliantMolecular targetsCancer therapeuticsDavid meekResponse inhibitors

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSean moranSeagen astellasAlexander spiraYuval cohenBruce mackleDanielp petrylakParaic kennySociety for immunotherapy of cancerSecurities exchangeCorbus pharmaceuticals reports third quarterProgram updatesYale school of medicineCorbus pharmaceuticalsLifesci advisors

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023.

United statesUnited kingdomBlack diamondMario corsoMark vellecaJulie seidelDrug administrationExchange commissionIvy brain tumor centerDevelopment expensesCompany masterkeyInternational conference on molecularDiamond therapeutics incMolecular targetsDiamond therapeuticsChief executive officer